LivaNova PLC (NASDAQ: LIVN) has experienced a striking surge in its stock value during the ongoing trading session, witnessing a notable uptick of 10.35% to $55.55. This occurrence has captured the keen attention of both investors and analysts following the revelation of its favorable clinical study outcomes.
LivaNova (LIVN) has today disclosed the findings from its OSPREY clinical investigation, “Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation,” which has attained a positive predictive outcome and is poised to wrap up its enrollment ahead of schedule. This development indicates a likelihood exceeding 97.5% for the OSPREY trial to successfully meet its primary endpoint.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
OSPREY represents a forward-looking, multi-center, randomized controlled open-label trial aimed at demonstrating the safety and efficacy of the aura6000 Hypoglossal Nerve Stimulator System compared to a non-stimulation control group among individuals grappling with moderate to severe obstructive sleep apnea (OSA) who have either failed or opted against positive airway pressure treatment.
LivaNova has apprised both the U.S. Food and Drug Administration (FDA) and its collaborative trial sites of this noteworthy milestone achieved in the OSPREY study. A planned interim analysis, in accordance with the approved protocol, has been conducted for the initial 90 participants enrolled in OSPREY.
Consequently, LivaNova is now able to project a high probability of achieving the primary endpoint in this distinctive randomized controlled trial without necessitating further patient enrollment. While this milestone underscores the company’s positive trajectory, ongoing follow-up visits for each participant will persist beyond the primary endpoint.
The primary efficacy endpoint of the OSPREY study aims to demonstrate that the responder rate of the apnea-hypopnea index (AHI) among subjects with device stimulation activated is statistically superior to that of subjects without stimulation after seven months of follow-up.
In the context of OSPREY, a response is defined as a minimum of 50% improvement from the baseline AHI, resulting in an AHI value below 20. Once the entire cohort completes the seven-month follow-up assessment and the results are collated, LivaNova will submit the final clinical dossier of OSPREY to the FDA.
Furthermore, the OSPREY study evaluates the safety of the aura6000 System and assesses patient quality of life through metrics such as daytime sleepiness.
